David Lovejoy
Plus aucun poste en cours
Fortune : 58 367 $ au 30/04/2024
Profil
David A.
Lovejoy was the founder of Protagenic Therapeutics, Inc. which was founded in 1994, where he held the title of Chief Scientific Officer.
He also held the position of Principal at the University of Toronto.
Dr. Lovejoy earned a doctorate degree from the University of Victoria.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 01/04/2024 | 37 200 ( 0,84% ) | 58 367 $ | 30/04/2024 |
Anciens postes connus de David Lovejoy
| Sociétés | Poste | Fin |
|---|---|---|
| University of Toronto | Corporate Officer/Principal | - |
| PROTAGENIC THERAPEUTICS, INC. | Fondateur | - |
Protagenic Therapeutics, Inc. /Old/
 Protagenic Therapeutics, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Protagenic Therapeutics, Inc. discovers and develops neuropeptides for the treatment of anxiety and depression based mood disorders. It focuses on the discovery and development of naturally occurring human brain hormones for the treatment of anxiety and depression based mood disorders. The firm products include PT00114 and PT00121, which are peptide-based formulations for the treatment of anxiety and depression disorders. The company is headquartered in New York, NY. | Directeur Technique/Scientifique/R&D | - |
Formation de David Lovejoy
| University of Victoria | Doctorate Degree |
Expériences
Fonctions occupées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| PROTAGENIC THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Protagenic Therapeutics, Inc. /Old/
Protagenic Therapeutics, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Protagenic Therapeutics, Inc. discovers and develops neuropeptides for the treatment of anxiety and depression based mood disorders. It focuses on the discovery and development of naturally occurring human brain hormones for the treatment of anxiety and depression based mood disorders. The firm products include PT00114 and PT00121, which are peptide-based formulations for the treatment of anxiety and depression disorders. The company is headquartered in New York, NY. | Health Technology |